01 Adoption of Automated Plasma Collection and Processing Advances in plasma collection technology are shifting the market toward automated systems that integrate plasma separation, donor monitoring, and collection into standardized workflows, reducing manual handling and improving processing consistency; the FDA cleared the NexSys PCS plasma collection system in February 2026 for automated collection of source plasma and plasma for transfusion.
02 Shift Toward Room-Temperature-Stable Plasma Products Drive Market Cold-chain requirements and limited access to frozen-storage infrastructure are encouraging the development of room-temperature-stable plasma products, allowing plasma to be transported and used in settings where conventional freezers are difficult to maintain; in July 2026, the FDA licensed EZPLAZ as the first freeze-dried plasma product in the U.S., with room-temperature stability and rapid reconstitution for emergency and remote settings.
01 Increasing Prevalence of Immunodeficiency Disorders and Expansion of Hospital-Based Transfusion Services Drive Market The increasing prevalence of immunodeficiency disorders is raising demand for plasma-derived immunoglobulins used in replacement therapy. Patients with primary or secondary antibody deficiencies require regular immunoglobulin treatment to maintain adequate immune protection and reduce recurrent infections. For example, intravenous immunoglobulin (IVIG) is used in patients with primary immunodeficiency to provide the antibodies their bodies cannot produce sufficiently. Higher treatment requirements increase demand for recovered plasma and encourage suppliers to maintain adequate fractionation and plasma-processing capacity. This sustained clinical need supports demand across the colloids (blood plasma) market.The expansion of hospital-based transfusion services is increasing demand for plasma products used in bleeding management and surgical care. Higher volumes of trauma treatment, complex surgeries, and critical-care procedures require hospitals to maintain sufficient plasma inventories for patients with significant blood loss or coagulation deficiencies. For example, fresh frozen plasma is administered to patients with multiple coagulation-factor deficiencies when rapid replacement is required. Greater hospital utilization increases procurement requirements for plasma products and strengthens demand across healthcare supply chains. The expansion of transfusion services therefore supports continued market demand for blood plasma products.
01 Shortage of Plasma Donors and Risk of Plasma-Derived Product Contamination Restrain Market Expansion An insufficient pool of regular plasma donors can restrict the volume of plasma available for collection and fractionation. Limited donor availability can create supply gaps and make it difficult for manufacturers and healthcare providers to maintain consistent inventories. These constraints can limit product availability and slow market expansion.Potential contamination during plasma collection, processing, or handling requires extensive screening, pathogen testing, and quality-control measures. These safeguards increase processing complexity, operating costs, and compliance requirements for plasma-derived products. Higher safety and production burdens can affect product availability and limit adoption across transfusion and therapeutic applications.
01 Development of Albumin-Based Therapeutic Products and Growth of Plasma Fractionation Capacity Offer Growth Opportunities Pharmaceutical companies and plasma-product manufacturers can target clinical applications for albumin in critical care, liver disorders, trauma, and severe burns. CSL Behring and Grifols offer albumin therapies, creating revenue through specialized formulations and hospital supply agreements. Additional albumin applications can expand product portfolios and improve the commercial value of processed plasma. Long-term hospital demand can also support recurring sales of albumin-based therapies.Plasma processors can expand fractionation facilities to convert collected plasma into albumin, immunoglobulins, and other therapeutic proteins. Grifols has invested in additional fractionation and purification capacity, supporting higher processing volumes. Higher capacity can support larger product volumes and strengthen revenue from plasma-derived medicin
01 Regulatory Differences Across Markets and Complex Plasma Fractionation and Product Consistency Hinders Growth Different requirements for plasma collection, donor eligibility, traceability, fractionation, and product approval increase the complexity of entering new geographic markets. For example, differences between U.S. and European plasma regulations can require manufacturers to maintain market-specific compliance processes, extending commercialization timelines and increasing operational complexity.Converting plasma into albumin, immunoglobulins, and other therapeutic products requires tightly controlled fractionation and purification processes. For example, immunoglobulin manufacturing involves multiple processing and quality-control stages, making capacity expansion difficult when facilities lack specialized fractionation infrastructure.
May 2026 Ingredion entered into a strategic partnership with Sanstar Limited to establish a joint venture focused on specialty ingredients, including pharmaceutical and food ingredient solutions. The collaboration included an equity investment by Ingredion and plans for a jointly owned platform in India to expand specialty ingredient manufacturing capabilities and strengthen formulation solutions across high-value applications.
April 2026 Roquette expanded its healthcare and pharmaceutical ingredient innovation activities by showcasing advanced excipient and formulation solutions. The company continued strengthening its portfolio of specialty ingredients used in pharmaceutical applications, supporting demand for functional colloidal and formulation technologies.
February 2026 Vegan Minerals expanded its international distribution network through a partnership with IMCD India for its WholeCal™ ingredient platform. The collaboration strengthened access to specialty nutrition and ingredient markets in India by combining Vegan Minerals’ ingredient technology with IMCD’s formulation and distribution capabilities.
January 2026 Aker BioMarine expanded its presence in India through new partnerships, leadership initiatives, and product innovation activities focused on nutrition ingredients. The company introduced new ingredient solutions and strengthened distribution strategies to support growing demand for advanced nutritional formulations.